Clinical Thyroidology® for the Public

Summaries for the Public from recent articles in Clinical Thyroidology
Table of Contents | PDF File for Saving and Printing

THYROID CANCER
2025 ATA Thyroid Cancer guidelines: Percutaneous thyroid ablation—who, when, why?

Instagram Youtube LinkedIn Facebook X

 

BACKGROUND
The majority of patients with thyroid cancer do very well. Indeed, almost 40% of thyroid cancers are less than 1 cm and have an excellent prognosis. This is because thyroid cancer is usually very slow growing and we have excellent treatment options, usually starting with surgery to remove the cancer. Indeed, small, low-risk thyroid cancers can often be followed by serial ultrasounds before moving to surgery if they grow, a treatment plan called active surveillance.

Percutaneous thermal ablation is a procedure where radiowave-based (radiofrequency ablation, RFA) or microwave-based (microwave ablation, MWA) heat delivered by a needle is used to destroy abnormal thyroid tissue. This has mainly been used to treat benign thyroid nodules, with the advantage being the lack of a scar. Recently, studies have been reported using RFA to treat small thyroid cancers without surgical resection. The 2015 ATA guidelines did not include thermal ablation as an initial management option for thyroid cancer. However, the 2025 guidelines formally recognize ultrasound-guided percutaneous ablation as an alternative to active surveillance or surgical resection for selected patients with small, low-risk thyroid cancer.

THE FULL ARTICLE TITLE
Ringel MD et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 2025;35(8):841-985.

SUMMARY OF THE STUDY
The 2025 ATA thyroid cancer guidelines refer to patients with differentiated thyroid cancer, almost all of which are papillary thyroid carcinoma.

New in these guidelines is the recommendation that ultrasound- guided percutaneous ablation may be considered as an alternative to active surveillance or surgical removal for selected patients with small, low-risk thyroid cancer. This recommendation is conditional and emphasizes shared decision-making.

Percutaneous ablation is less likely to result in hypothyroidism than lobectomy, but provides less certainty of complete cancer destruction, with no tissue to examine after the ablation. Studies have shown favorable results, with low recurrence rates and low complication rates, including major complications. A review of 36 studies taken together reported complete disappearance after RFA in approximately 91% of these small cancers, with local recurrence rates of approximately 2 to 3% and spread to the lymph nodes occurring in 1 to 2% of cases.

Longer-term series have also shown favorable results. A large study of 1613 patients with cancer ≤2 cm treated with RFA reported cancer progression in 4.3% of patients over almost 5 years. Outcomes were less favorable with larger cancers and multiple cancers within the thyroid.

Overall, patient selection is critical. The most favorable outcomes are reported in small, single cancers within the thyroid without spread to the lymph nodes. Patients treated with percutaneous ablation still require long-term ultrasound surveillance. Finally, outcomes are operatordependent. Thyroid cancer ablation should be performed by clinicians with experience in thyroid ultrasonography, biopsy, thyroid ablation, and management of procedural complications.

WHAT ARE THE IMPLICATIONS OF THIS STUDY?
The 2025 ATA guidelines recognize percutaneous ablation as a reasonable option for selected patients with small thyroid cancers. Cancer progression and complication rates are low in experienced centers, but long-term remission data remain less established than for surgery.

— Alan P. Farwell, MD

ABBREVIATIONS & DEFINITIONS

Radiofrequency ablation (RFA): a procedure using radiowave-based heat delivered by a needle to destroy abnormal tissue or lymph nodes containing cancer.

Microwave ablation (MVA): a procedure where a very thin needle is inserted into a thyroid nodule then uses microwave-based heat delivered by a needle to destroy abnormal tissue or lymph nodes containing cancer.

Thermal ablation: using heat delivered by a needle to destroy abnormal tissue or lymph nodes containing cancer. There are 3 types of thermal ablation: radiowavebased heat (radiofrequency ablation, RFA), microwavebased heat and laser-based heat.

Active Surveillance: following a small, low-risk thyroid cancer with ultrasound and deferring surgery until the cancer grows significantly.

Papillary thyroid cancer: the most common type of differentiated thyroid cancer. There are 4 variants of papillary thyroid cancer: classic, follicular, tall-cell and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Thyroidectomy: surgery to remove the entire thyroid gland. When the entire thyroid is removed it is termed a total thyroidectomy. When less is removed, such as in removal of a lobe, it is termed a partial thyroidectomy.

Thyroid Ultrasound: a common imaging test used to evaluate the structure of the thyroid gland. Ultrasound uses soundwaves to create a picture of the structure of the thyroid gland and accurately identify and characterize nodules within the thyroid. Ultrasound is also frequently used to guide the needle into a nodule during a thyroid nodule biopsy.